Gleamer Charts Multi-Modality Future With FDA Nod And MRI Acquisitions

The French Start-up Is Laying Groundwork For A Full-Suite Diagnostic Platform Across X-Ray, CT And MRI.

ChestView, Gleamer’s newly FDA-cleared solution, is designed for chest X-ray interpretation and is the latest addition to its Gleamer Copilot suite. ChestView, which operates as a computer-aided detection system that can simultaneously detect multiple pathologies on images to support radiologists, is being rolled out in the US.

The FDA clearance expands Gleamer’s Copilot suite footprint in the US market.
Key Takeaways

· Gleamer CEO Allouche sees CADe-style annotation as critical to clinician trust and AI adoption in high-volume imaging tasks.

· Whole-body MRI remains off the table for now, with Gleamer focusing on enhancing existing care pathways.

· Predictive support, real-world evidence, and computing advances will shape AI’s clinical relevance in the next five years.

As radiologists contend with heavier caseloads and shrinking time to interpret images, artificial intelligence (AI) is emerging not just as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diagnostic Imaging

More from Medtech Insight

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.

Corify Care, Mayo Clinic Join Forces To Advance AI-Driven Global Cardiac Mapping Platform

 
• By 

Corify Care’s CEO said the company aims to submit its 510(k) application to the US FDA by year-end, targeting market clearance in 2026. The company hopes its collaboration with the Mayo Clinic will help speed adoption of ACORYS, a noninvasive mapping technology for use in complex cardiac ablations.